BIOMARKERS FOR THE PREDICTION OF RENAL INJURY

• US 20110003708A1
• Filed: 06/25/2010
• Published: 01/06/2011
• Est. Priority Date: 12/27/2007
• Status: Abandoned Application

• Current Assignee: Compugen Ltd
• Original Assignee: Compugen Ltd
• Inventors: Kinar, Yaron, Cojocaru, Gad S., Furman, Yael, Beiman, Merav, Novik, Amit, Pergam, Tania, Walach, Shira, Sameah-Greenwald, Shirley, Montia, Eve, Cohen-Dayag, Anat
• Application Number:
  US12/824,010
• Publication Number:
  US 20110003708A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/142 Toxicological screening, e.g. expression profiles which identify toxicity
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The present invention relates to means and methods for predicting the onset of renal injury based on measuring the expression of polynucleotides and proteins, particularly on measuring the expression of sets of novel as well as known polynucleotides and proteins, and to kits utilizing same.

Claims

1. A diagnostic marker selected from an isolated polynucleotide comprising the nucleic acid sequence set forth in any one of SEQ. ID NOs:

2, 4, 5, 7, 8, 10, 11, 13, 14, 16-19, 21-23, 25, 26, 28, 29, 31, 33, 35, 37, 39, 41, or a nucleic acid sequence having at least 90% identity to said sequence set forth in any one of SEQ ID NOs;

2, 4, 5, 7, 8, 10, 11, 13, 14, 16-19, 21-23, 25, 26, 28, 29, 31, 33, 35, 37, 39, 41, wherein the polynucleotide is present in at least one of a kidney tissue, body fluid or body secretion.

2. The diagnostic marker of claim 1, wherein the nucleic acid sequence has at least 95% identity to the sequence set forth in any one of SEQ ID NOs:

2, 4, 5, 7, 8, 10, 11, 13, 14, 16-19, 21-23, 25, 26, 28, 29, 31, 33, 35, 37, 39, 41.

3. The diagnostic marker of claim 1, wherein the isolated polynucleotide consists of the nucleic acid sequence set forth in any one of SEQ. ID NOs:

2, 4, 5, 7, 8, 10, 11, 13, 14, 16-19, 21-23, 25, 26, 28, 29, 31, 33, 35, 37, 39, 41.

4. The diagnostic marker of claim 1, wherein the isolated polynucleotide encodes a protein having the amino acid sequence as set forth in any one of SEQ ID NOs:

62-71, 141, 143, 144, 146-153, 155, 156, 158-160, 162, 167-169, 172, 174-176, 210-214, 218, 219, 221-225, 227-228, 233, 235, 236.

5. The diagnostic marker of claim 1, wherein the isolated polynucleotide is at least 85% homologous to any one of SEQ. ID NOs:

1, 3, 6, 9, 12, 15, 20, 24, 27, 30, 32, 34, 36, 38, 40, 82, 84-90, 92, 94, 95-99, 101-104, 106-108, 110, 111, 113, 114, 116-119, 133, 135-137, 178, 180-185, 189-190, 192-196, 198, 199, 203, 206, 207.

6. The diagnostic marker of claim 5, wherein the isolated polynucleotide is at least 95% homologous to any one of:

1, 3, 6, 9, 12, 15, 20, 24, 27, 30, 32, 34, 36, 38, 40, 82, 84-90, 92, 94, 95-99, 101-104, 106-108, 110, 111, 113, 114, 116-119, 133, 135-137, 178, 180-185, 189-190, 192-196, 198, 199, 203, 206, 207.

7. The diagnostic marker of claim 6, wherein the isolated polynucleotide has the nucleic acid sequence as set forth in any one of SEQ. ID NOs:

1, 3, 6, 9, 12, 15, 20, 24, 27, 30, 32, 34, 36, 38, 40, 82, 84-90, 92, 94, 95-99, 101-104, 106-108, 110, 111, 113, 114, 116-119, 133, 135-137, 178, 180-185, 189-190, 192-196, 198, 199, 203, 206, 207.

8. A method for predicting the onset of renal injury in a subject, comprising detecting in a sample obtained from said subject at least one diagnostic marker according to claim 7.

9. A method for predicting onset of renal injury caused by treatment with a compound, comprising (a) administering a dose of the compound to at least one test subject;

(b) after a selected time period, obtaining a biological sample from the at least one subject;

(c) measuring in the biological sample the expression level of at least two polynucleotide markers corresponding to sequences within at least two Candidates selected from ID NOs;

1, 5, 6, 12, 15 and 16; and

(d) determining whether the sample is in the positive class for onset of renal injury using a classifier comprising at least the two markers for which the expression level is measured.

10. The method of claim 9, wherein the polynucleotide marker corresponding to sequences within the Candidates selected from ID NOs:

1, 5, 6, 12, 15, 16 is selected from the group consisting of;

a transcript having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

1, 3, 48, 6, 12, and 52;

a node having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

2, 4, 5, 49, 7, 8, 13, 14, and 53; and

an amplicon having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

254, 266, 329, 263, 287, 296, 290, and 332, and homologs thereto.

11. The method of claim 9, wherein the expression level of a set of four polynucleotide markers is measured, the markers corresponding to sequences within Candidates selected from ID NOs:

1, 5, 12 and 15 respectively, corresponding to genes listed in Table 13, wherein the set of four polynucleotide markers is selected from the group consisting of;

transcripts having the nucleic acid sequence as set forth in SEQ ID NOs;

1, 3, 6, 12;

nodes having the nucleic acid sequence as set forth in SEQ ID NOs;

2, 4, 5, 7, 8, 13 and 14, and amplicons having the nucleic acid sequence as set forth in SEQ ID NOs;

254, 266, 287, 296, and 329, and homologous thereto, and wherein said expression of said set of four markers is indicative of the onset of renal injury.

12. The method of claim 9, wherein the expression level of a set of four polynucleotide markers is measured, the markers corresponding to sequences within Candidates selected from ID NOs:

1, 5, 6 and 16, respectively, corresponding to genes listed in Table 26, wherein the set of four polynucleotide markers is selected from the group consisting of;

transcripts having the nucleic acid sequence as set forth in SEQ ID NOs;

1, 3, 48, 52;

nodes having the nucleic acid sequence as set forth in SEQ ID NOs;

2, 4, 5, 49, and 53; and

amplicons having the nucleic acid sequence as set forth in SEQ ID NOs;

254, 266, 329, 263, 290, and 332, and homologs thereto, and wherein said expression of said set of four markers is indicative of the onset of renal injury.

13. The method of claim 9 wherein the expression level of a set of six polynucleotide markers is measured, the markers corresponding to sequences within Candidates selected from ID NOs:

1, 5, 6, 12, 15 and 16, respectively, corresponding to genes listed in Table 27, wherein the set of six polynucleotide markers is selected from the group consisting of;

transcripts having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

1, 3, 6, 12, 48, 52;

nodes having the nucleic acid sequence as set forth in SEQ ID NOs;

2, 4, 5, 7, 8, 13, 14, 49, and 53; and

amplicons having the nucleic acid sequence as set forth in SEQ ID NOs;

254, 266, 329, 263, 287, 290, 296, and 332 and homologs thereto, and wherein said expression of said set of six markers is indicative of the onset of renal injury.

14. The method of claim 9, wherein the biological sample is selected from the group consisting of kidney tissue, body fluid and body secretion.

15. The method of claim 9, wherein the test compound is nephrotoxic agent selected from the group consisting of aminoglycosides;

platinum based chemotherapy agents;

heavy metals;

DNA interacting drugs;

antifungal agents;

proximal tubule damaging agents; and

vasoconstriction compounds.

16. The method of claim 9, wherein the renal injury is associated with at least one kidney disease or pathology, selected from the group consisting of nephrotoxicity, renal toxicity, nephritis, kidney necrosis, kidney damage, glomerular and tubular injury, focal segmental glomerulosclerosis, kidney dysfunction, nephritic syndrome, acute renal failure, chronic renal failure, proximal tubal dysfunction, acute kidney transplant rejection and chronic kidney transplant refection.

17. The method of claim 9, wherein the selected time period after which the sample is obtained from the test subject is prior to or at the onset of the appearance of histopathological or clinical indications of renal injury.

18. The method of claim 17, wherein the selected time period is selected from the group consisting of about 1 day, about 5 days, about 7 days, about 14 days, about 21 and about 28 days after administration of the test compound.

19. The method of claim 16, wherein the selected time period is 1 day or less.

20. The method of claim 9, wherein the level of expression is detected by an amplification or hybridization assay.

21. The method of claim 20, wherein the amplification assay is selected from the group consisting of quantitative or semi-quantitative PCR, Northern blot, dot or slot blot, nuclease protection and microarray assays.

22. An isolated polynucleotide probe or primer comprising a nucleic acid sequence that specifically hybridizes to a marker having a nucleic acid sequence as set forth in any one of SEQ ID NOs:

1, 3, 6, 12, 48, 52, 2, 4, 5, 8, 13, 14, 49, 53, 254, 266, 329, 263, 287, 290, 296, and 332.

23. The isolated polynucleotide probe or primer of claim 22, consisting of a nucleic acid sequence set forth in any one of SEQ ID NOs:

252-253, 261-262, 264-265, 285-286, 288-289, 294-295, 327-328, 330-331.

24. A kit for detecting renal injury, comprising at least two probes or pairs of primers and reagents for detecting at least two polynucleotide markers corresponding to sequences within any one of Candidates of ID NOs:

1, 5, 6, 12, 15 and 16.

25. The kit of claim 24, wherein the polynucleotide marker corresponding to sequences within the Candidates selected from ID NOs:

1, 5, 6, 12, 15 and 16 respectively, is selected from the group consisting of;

a transcript having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

1, 3, 48, 6, 12, and 52;

a node having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

2, 4, 5, 49, 7, 8, 13, 14, 53; and

an amplicon having the nucleic acid sequence as set forth in any one of SEQ ID NOs;

254, 266, 329, 263, 287, 296, 290, and 332 and homologs thereto.

26. The kit of claim 25, comprising a plurality of primers or probes for detecting a set of four markers corresponding to sequences within the Candidates selected from ID NOs:

1, 5, 12 and 15 respectively, corresponding to genes listed in Table 13, wherein the set of markers is selected from the group consisting of;

transcripts having the nucleic acid sequence as set forth in SEQ ID NOs;

1, 3, 6, 12;

nodes having the nucleic acid sequence as set forth in SEQ ID NOs;

2, 4, 5, 7, 8, 13 and 14; and

amplicons having the nucleic acid sequence as set forth in SEQ ID NOs;

254, 266, 287, 296, and 329, and homologs thereto.

27. The kit of claim 25, comprising a plurality of primers or probes for detecting a set of four markers corresponding to the sequences within Candidates selected from ID NOs:

1, 5, 6 and 16 respectively, corresponding to genes listed in Table 26, wherein the set of markers is selected from the group consisting of transcripts having the nucleic acid sequence as set forth in SEQ ID NOs;

1, 3, 48, 52;

nodes having the nucleic acid sequence as set forth in SEQ ID NOs;

2, 4, 5, 49, and 53; and

amplicons having the nucleic acid sequence as set forth in SEQ ID NOs;

254, 266, 329, 263, 290, and 332, and homologs thereto.

28. The kit of claim 25, comprising a plurality of primers or probes for detecting a set of six markers corresponding to sequences within the Candidates selected from ID NOs:

1, 5, 6, 12, 15 and 16 respectively, corresponding to genes listed in Table 27, wherein the set of markers is selected from the group consisting of transcripts having the nucleic acid sequence as set forth in SEQ ID NOs;

1, 3, 6, 12, 48, 52;

nodes having the nucleic acid sequence as set forth in SEQ ID NOs;

2, 4, 5, 7, 8, 13, 14, 49, and 53; and

amplicons having the nucleic acid sequence as set forth in SEQ ID NOs;

254, 266, 329, 263, 290, 287, 296, and 332 and homologous thereto.

29. The kit of claim 24, comprising at least two probes or pair of primers corresponding to sequences within at least two Candidates selected from ID NOs:

1, 5, 6, 12, 15 and 16, respectively, the probes or primers having the nucleic acid sequence selected from the group consisting of SEQ ID NOs;

252-253;

261-262;

264-265;

327-328;

285-286;

288-289;

294-295;

330-331.

30. The kit of claim 24, comprising at least two probes or pair of primers corresponding to sequences within at least two Candidates selected from ID NOs:

1, 5, 6, 12, 15 and 16 respectively, the probes or primers having the nucleic acid sequence selected from the group consisting of SEQ ID NOs;

252-253;

261-262;

264-265;

327-328;

285-286;

288-289;

294-295;

330-331.

31. The kit of claim 24, wherein the reagents for detecting the at least two marker are reagents for employing a NAT-based technology.

32. The kit of claim 31, wherein the NAT-based assay is selected from the group consisting of a PCR, Real-Time PCR, LCR, Self-Sustained Synthetic Reaction, Q-Beta Replicase, Cycling Probe Reaction, Branched DNA, RFLP analysis, DGGE/TGGE, Single-Strand Conformation Polymorphism, Dideoxy Fingerprinting, Microarrays, Fluorescence In Situ Hybridization and Comparative Genomic Hybridization.